QSAR studies on aminothiazole derivatives as aurora a kinase inhibitors.
Quantitative structure-activity relationship studies on 54 aminothiazole derivatives as Aurora A kinase inhibitors were performed to explore the important factors affecting their biologic activity. For 2D-quantitative structure-activity relationship study, genetic algorithm combined with multiple linear regression was used to select significant molecular descriptors. The MLR model gave squared correlation coefficient of 0.828 and squared cross-validated correlation coefficient of 0.771 for the training set compounds. Comparative molecular field analysis and comparative molecular similarity indices analysis were used to develop 3D-quantitative structure-activity relationship models. The comparative molecular field analysis model gave cross-validated correlation coefficient q² of 0.695 and non-cross-validated correlation coefficient r² of 0.977. For comparative molecular similarity indices analysis model, the corresponding q² and r² were 0.698 and 0.960, respectively. The proposed 3D-quantitative structure-activity relationship models were validated by the test set compounds not used in the modeling process, with r²(pred) values of 0.788 for comparative molecular field analysis and 0.798 for comparative molecular similarity indices analysis. The 3D contour maps suggested that further modification of the aniline group of compound 22 considering electrostatic, hydrophobic and hydrogen bond properties would influence the inhibitory activity. The results from quantitative structure-activity relationship models would be very useful to understand the structure-activity relationship of these inhibitors and to guide the further structural modification of new potential inhibitors.
Department of Chemistry, Lanzhou University, Lanzhou, China School of Pharmacy, Lanzhou University, Lanzhou, China.
Jin
J
Qin
Lili
L
Xi
Juan
J
Du
Huanxiang
H
Liu
Xiaojun
X
Yao
D000588:Amines / Q000737:chemistry / Q000494:pharmacology*; D064127:Aurora Kinases; D001665:Binding Sites; D018360:Crystallography, X-Ray; D015195:Drug Design; D004789:Enzyme Activation / Q000187:drug effects*; D020128:Inhibitory Concentration 50; D008958:Models, Molecular; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D021281:Quantitative Structure-Activity Relationship; D013844:Thiazoles / Q000737:chemistry / Q000494:pharmacology*
D000588:Amines; D047428:Protein Kinase Inhibitors; D013844:Thiazoles; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases